2018 Pre-Eclampsia Drug Development- Pipeline Analysis Report
Preeclampsia is a multi-system pregnancy related condition affecting patients in their second or third trimester. The condition affects around 5% to 8% of pregnancies and presents serious health consequences to mothers and babies. Currently, no treatment has been approved by US FDA despite preeclampsia causing fetal and maternal mortality. It is characterized difficult to control hypertension and can damage end organs forcing immediate delivery so that it does not progress to the mother. It is caused by diverse placental dysfunctions.
Preeclampsia pipeline comprises of 9 drugs under active development as of April 2018. Of these, 2 drugs are in Phase 1 and 2 drugs in Phase 3. Further, 4 drugs are in Pre-clinical stage and 1 drug in research phase.
13 companies are developing the pipeline for Preeclampsia. Of this, rEVO Biologics, Inc has the highest phase compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is cell replacements.
Three compounds have been awarded orphan drug status for Preeclampsia.
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Pre-eclampsia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Pre-eclampsia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Pre-eclampsia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Preeclampsia pipeline comprises of 9 drugs under active development as of April 2018. Of these, 2 drugs are in Phase 1 and 2 drugs in Phase 3. Further, 4 drugs are in Pre-clinical stage and 1 drug in research phase.
13 companies are developing the pipeline for Preeclampsia. Of this, rEVO Biologics, Inc has the highest phase compounds in pipeline. Mechanism of Action of most of the therapeutic candidates is cell replacements.
Three compounds have been awarded orphan drug status for Preeclampsia.
To assist researchers and business development managers, VPA Research has come up with a comprehensive report on Pre-eclampsia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Pre-eclampsia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Pre-eclampsia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 PREECLAMPSIA- COMPANY WISE PIPELINE ANALYSIS
3.1 A1M Pharma AB. PIPELINE, H1 2018
3.2 Adepthera LLC PIPELINE, H1 2018
3.3 Alnylam Pharmaceuticals, Inc. PIPELINE, H1 2018
3.4 Berlin Cures GmbH PIPELINE, H1 2018
3.5 Glenveigh Medical, LLC PIPELINE, H1 2018
3.6 Pluristem Therapeutics PIPELINE, H1 2018
3.7 rEVO Biologics, Inc PIPELINE, H1 2018
3.8 Silence Therapeutics plc PIPELINE, H1 2018
3.9 VG Life Sciences, Inc. PIPELINE, H1 2018
4 PREECLAMPSIA DRUG SNAPSHOTS
4.1 GPCR-AAB binding aptamers Drug Details
4.1.1 Snapshot-
4.1.2 Drug Details
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Results
4.2 SiRNA (Silence Therapeutics)
4.2.1 Snapshot
4.2.2 Drug Details
4.2.3 Mechanism of Action
4.2.4 Current Status
4.3 Hormonal therapy (Adepthera) Details
4.3.1 Snapshot-
4.3.2 Drug Details
4.3.3 Mechanism of Action
4.3.4 Current Status
4.4 ROSgard Drug Details
4.4.1 Snapshot-
4.4.2 Drug Details
4.4.3 Mechanism of Action
4.4.4 Current Status
4.5 RNAI THERAPEUTIC TARGETING ANGIOTENSINOGEN (AGT) Drug Details
4.5.1 Snapshot-
4.5.2 Drug Details
4.5.3 Mechanism of Action
4.5.4 Current Status
4.6 Digoxin Immune Fab (DIF) Drug Details
4.6.1 Snapshot-
4.6.2 Drug Details
4.6.3 Mechanism of Action
4.6.4 Current Status
4.7 recombinant human antithrombin Drug Details
4.7.1 Snapshot-
4.7.2 Drug Details
4.7.3 Mechanism of Action
4.7.4 Current Status
4.7.5 Trial Details
4.8 VG1177 Drug Details
4.8.1 Snapshot-
4.8.2 Drug Details
4.8.3 Mechanism of Action
4.8.4 Current Status
4.9 PLX PAD Drug Details
4.9.1 Snapshot-
4.9.2 Drug Details
4.9.3 Mechanism of Action
4.9.4 Current Status
5 RECENT DEVELOPMENTS IN PREECLAMPSIA PIPELINE
5.1 BC007 Eliminates Autoantibodies Linked to Disease in 80% of Patients- 2018
5.2 A1M Pharma submits application to the Swedish Medical Products Agency to conduct clinical phase I study with ROSgard- 2018
5.3 AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study Conducted by Velo Bio- 2017
5.4 VGLS Patented Drug Vg1177 Shows Impact In Fighting Hypertension, Kidney Injury- 2015
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
1.1 LIST OF FIGURES
1.2 LIST OF TABLES
2 EXECUTIVE SUMMARY
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION
3 PREECLAMPSIA- COMPANY WISE PIPELINE ANALYSIS
3.1 A1M Pharma AB. PIPELINE, H1 2018
3.2 Adepthera LLC PIPELINE, H1 2018
3.3 Alnylam Pharmaceuticals, Inc. PIPELINE, H1 2018
3.4 Berlin Cures GmbH PIPELINE, H1 2018
3.5 Glenveigh Medical, LLC PIPELINE, H1 2018
3.6 Pluristem Therapeutics PIPELINE, H1 2018
3.7 rEVO Biologics, Inc PIPELINE, H1 2018
3.8 Silence Therapeutics plc PIPELINE, H1 2018
3.9 VG Life Sciences, Inc. PIPELINE, H1 2018
4 PREECLAMPSIA DRUG SNAPSHOTS
4.1 GPCR-AAB binding aptamers Drug Details
4.1.1 Snapshot-
4.1.2 Drug Details
4.1.3 Mechanism of Action
4.1.4 Current Status
4.1.5 Trial Results
4.2 SiRNA (Silence Therapeutics)
4.2.1 Snapshot
4.2.2 Drug Details
4.2.3 Mechanism of Action
4.2.4 Current Status
4.3 Hormonal therapy (Adepthera) Details
4.3.1 Snapshot-
4.3.2 Drug Details
4.3.3 Mechanism of Action
4.3.4 Current Status
4.4 ROSgard Drug Details
4.4.1 Snapshot-
4.4.2 Drug Details
4.4.3 Mechanism of Action
4.4.4 Current Status
4.5 RNAI THERAPEUTIC TARGETING ANGIOTENSINOGEN (AGT) Drug Details
4.5.1 Snapshot-
4.5.2 Drug Details
4.5.3 Mechanism of Action
4.5.4 Current Status
4.6 Digoxin Immune Fab (DIF) Drug Details
4.6.1 Snapshot-
4.6.2 Drug Details
4.6.3 Mechanism of Action
4.6.4 Current Status
4.7 recombinant human antithrombin Drug Details
4.7.1 Snapshot-
4.7.2 Drug Details
4.7.3 Mechanism of Action
4.7.4 Current Status
4.7.5 Trial Details
4.8 VG1177 Drug Details
4.8.1 Snapshot-
4.8.2 Drug Details
4.8.3 Mechanism of Action
4.8.4 Current Status
4.9 PLX PAD Drug Details
4.9.1 Snapshot-
4.9.2 Drug Details
4.9.3 Mechanism of Action
4.9.4 Current Status
5 RECENT DEVELOPMENTS IN PREECLAMPSIA PIPELINE
5.1 BC007 Eliminates Autoantibodies Linked to Disease in 80% of Patients- 2018
5.2 A1M Pharma submits application to the Swedish Medical Products Agency to conduct clinical phase I study with ROSgard- 2018
5.3 AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study Conducted by Velo Bio- 2017
5.4 VGLS Patented Drug Vg1177 Shows Impact In Fighting Hypertension, Kidney Injury- 2015
6 APPENDIX
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY
LIST OF FIGURES
Figure 1: Preeclampsia Pipeline by Phase, H1- 2018
Figure 2: Preeclampsia Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Preeclampsia Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
Figure 1: Preeclampsia Pipeline by Phase, H1- 2018
Figure 2: Preeclampsia Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Preeclampsia Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Preeclampsia Pipeline by Phase, H1- 2018
Table 2: Preeclampsia Pipeline by Companies, H1- 2018 (1)
Table 3: Preeclampsia Pipeline by Mechanism of Action, H1- 2018
Table 4: A1M Pharma AB Preeclampsia Pipeline, H1- 2018
Table 5: Adepthera LLC- Preeclampsia Pipeline, H1- 2018
Table 6: Alnylam Pharmaceuticals, Inc.- Preeclampsia Pipeline, H1- 2018
Table 7: Berlin Cures GmbH- Preeclampsia Pipeline, H1- 2018
Table 8: Glenveigh Medical, LLC- Preeclampsia Pipeline, H1- 2018
Table 9: Pluristem Therapeutics- Preeclampsia Pipeline, H1- 2018
Table 10: rEVO Biologics, Inc- Preeclampsia Pipeline, H1- 2018
Table 11: Silence Therapeutics plc- Preeclampsia Pipeline, H1- 2018
Table 12: VG Life Sciences, Inc.- Preeclampsia Pipeline, H1- 2018
Table 1: Preeclampsia Pipeline by Phase, H1- 2018
Table 2: Preeclampsia Pipeline by Companies, H1- 2018 (1)
Table 3: Preeclampsia Pipeline by Mechanism of Action, H1- 2018
Table 4: A1M Pharma AB Preeclampsia Pipeline, H1- 2018
Table 5: Adepthera LLC- Preeclampsia Pipeline, H1- 2018
Table 6: Alnylam Pharmaceuticals, Inc.- Preeclampsia Pipeline, H1- 2018
Table 7: Berlin Cures GmbH- Preeclampsia Pipeline, H1- 2018
Table 8: Glenveigh Medical, LLC- Preeclampsia Pipeline, H1- 2018
Table 9: Pluristem Therapeutics- Preeclampsia Pipeline, H1- 2018
Table 10: rEVO Biologics, Inc- Preeclampsia Pipeline, H1- 2018
Table 11: Silence Therapeutics plc- Preeclampsia Pipeline, H1- 2018
Table 12: VG Life Sciences, Inc.- Preeclampsia Pipeline, H1- 2018
